ArticleNature biomedical engineering2024
Reinforcement of the intestinal mucosal barrier via mucus-penetrating PEGylated bacteria.
Article in Nature biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Enabling Clinical Translation of Oral Probiotics Through Formulation Engineering and Scalable Manufacturing.Biotechnology journal · 2026Pooled it
- Dynamic feedback BacGuard anchors microbial metabolism to host symbiosis in real-time ulcerative colitis therapy.Bioactive materials · 2026Article
- Probiotic Spore Inspired Oral Drug Delivery System With Multiple-Barriers-Crossing Ability Modulates Gut-Brain Axis for Parkinson's Disease Therapy.Exploration (Beijing, China) · 2026Article
- Dopamine polymerization-mediated surface functionalization of living cells for advanced therapeutic applications.Nature protocols · 2026Review
- Advances of oral micro- and nanomedicines for modulating intestinal barriers in the treatment of intestinal diseases.Acta pharmaceutica Sinica. B · 2026Review
- Gut mucosal barrier: the frontline of bidirectional regulation of the gut-X axis.Medical review (2021) · 2026Review
- Oral probiotic delivery-based therapeutic strategies for inflammatory bowel disease.Asian journal of pharmaceutical sciences · 2026Review
- From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine.Journal of hematology & oncology · 2026Review
- Intestinal Source Control of Lipid Metabolism by Enzyme-Probiotic Encapsulated, Spatiotemporal Crosslinked, and Small Intestine-Adhesive Hydrogel Microspheres.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Polysaccharide-Based Encapsulation of Microbes for Enhanced Microbial Therapy.Polymer science & technology (Washington, D.C.) · 2026Review
- Prodrug-integrated multifunctional liposome encapsulation enhances probiotic-based bacteriotherapy for inflammatory bowel disease.Materials today. Bio · 2026Article
- Oral delivery of enterocyte-mimetic butyrate-loaded nanoparticles repairs the gut barrier and inhibits growth of digestive system tumors.Nature communications · 2026Article
- Dual-Key Genetic Circuit Enables Stable and Self-Regulated Engineered Bacteria for the Treatment of Ulcerative Colitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An orally administrable hydrogen-bonded organic framework (HOF)-based nanoreactor to reprogram metabolism for senescence intervention.National science review · 2026Article
- Ellagic acid can improve stroke by regulating gut microbiota.Metabolic brain disease · 2026Review
- Surface decoration of bacteria generates robust living therapeutics for improved ulcerative colitis therapy.Communications biology · 2026Article
- A montmorillonite-based oral fermentation system enables long-lasting in-situ biosynthesis to restore intestinal homeostasis.Nature communications · 2026Article
- Bacteriocin-transport-inspired oral peptide-probiotic delivery ameliorates IBD complications via autophagy and gut homeostasis.Science advances · 2026Article
- A softness zwitterionic micelles efficiently deliver inhaled nintedanib by enhancing airway mucus penetration.Science advances · 2026Article
- Metabolic regulatory mechanisms of Yijinjing exercise in patients with type 2 diabetes mellitus: Insight from the gut microbiota-intestinal barrier- inflammation axis.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The breakdown of the gut's mucosal barrier that prevents the infiltration of microorganisms, inflammatory cytokines and toxins into bodily tissues can lead to inflammatory bowel disease and to metabolic and autoimmune diseases. Here we show that the intestinal mucosal barrier can be reinforced via the oral administration of commensal bacteria coated with poly(ethylene glycol) (PEG) to facilitate their penetration into mucus. In mice with intestinal homoeostatic imbalance, mucus-penetrating PEGylated bacteria preferentially localized in mucus at the lower gastrointestinal tract, inhibited the invasion of pathogenic bacteria, maintained homoeostasis of the gut microbiota, stimulated the secretion of mucus and the expression of tight junctions, and prevented the mice from developing colitis and diabetes. Orally delivered PEGylated bacteria may help prevent and treat gastrointestinal disorders.
Indexed as
Identifiers
38839928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.